FDA final guidance on 'Dear Healthcare Provider' letters

April 2014
CenterWatch Monthly;Apr2014, Vol. 21 Issue 4, p6
The article reports that a guidance document titled "Dear Health Care Provider Letters: Improving Communication of Important Safety Information," has been released by the Food & Drug Administration (FDA). It offers information on the content and format of Dear Healthcare Provider (DHCP) letters which are used by drug manufacturers to communicate with healthcare providers regarding a drug warning, or change in prescribing information or drug promotional labeling or advertising.


Related Articles

  • Would Washington's FDA Fix Cure the Patients or the Drug Industry? MacGillis, Alec // Pro Publica;Oct2015, p44 

    The article discusses whether the 21st Century Cures Act will benefit the patients or the drug industry in the U.S. The bill will provide significant federal medical research funding for the National Institutes of Health (NIH). Former Food and Drug Administration (FDA) officials have criticized...

  • FDA scrutiny threatens DTC media bonanza. Thomaselli, Rich; Atkinson, Claire; Fine, Jon // Advertising Age;4/25/2005, Vol. 76 Issue 17, p1 

    Reports the impact of the warning letters issued by the U.S. Food and Drug Administration to drugmakers that violated promotional regulations in terms of direct-to-consumer advertising. Action taken by drugmakers in response to the warning; Impact on television and cable networks; Decision of...

  • FDA steps-up warnings, low level enforcement.  // Medical Marketing & Media;May98, Vol. 33 Issue 5, p32 

    States that the United States Food and Drug Administration issued warning letters to pharmaceutical companies, but have not enforced penalties. Reasons penalties were not enforced; Identification of companies receiving letters; Comments from Michael Peskoe, assistant general counsel, regulatory...

  • TV Drug Ads: What You Don't See. Henry, Sarah; Lehrman, Sally; Motte, Paula // Health (Time Inc. Health);Nov/Dec97, Vol. 11 Issue 8, p24 

    Reports on the decision of the U.S. Food and Drug Administration to allow drug companies to advertise their products as it comply with the agency's broadcast guidelines. Requirements for the advertising of drugs.

  • FDA to speed up DTC regulatory actions.  // Formulary;Feb2003, Vol. 38 Issue 2, p115 

    Discusses the results of a report on direct-to-consumer (DTC) advertising from the General Accounting Office in the U.S. Impact of the DTC on pharmaceutical companies; DTC advertising spending; Effort of the U.S. Food and Drug Administration to regulate DTC advertising.

  • Internet poses challenge for FDA, drug makers. Reed, Kristin // Inside Tucson Business;08/18/97, Vol. 7 Issue 21, p9B 

    Details on the challenge posed by the Internet for the US Food and Drug Administration (FDA) in enforcing rules that bar claims about the benefits of drugs or devices with no marketing clearance. Warning received by Gynecare Inc. from the FDA over marketing violations on the Internet;...

  • Pharmaceutical advertisements in leading medical journals: experts' assessments. Wilkes, Michael S.; Doblin, Bruce H.; Shapiro, Martin F.; Wilkes, M S; Doblin, B H; Shapiro, M F // Annals of Internal Medicine;6/1/92, Vol. 116 Issue 11, p912 

    Objective: To assess both the accuracy of scientific data presented in print pharmaceutical advertisements and the compliance of these advertisements with current Food and Drug Administration (FDA) standards.Design: Cross-sectional survey.Measurements: Each...

  • Addressing the problem of misleading advertising. Kessler, David A.; Kessler, D A // Annals of Internal Medicine;6/1/92, Vol. 116 Issue 11, p950 

    Editorial. Focuses on advertisements with misleading information and violation of U.S. Food and Drug Administration regulations governing the accuracy and balance of prescription drug advertisements. Accuracy and balance of scientific information presented in a promotional rather than a...

  • Disorders made to order. Koerner, Brendan I. // Mother Jones;Jul/Aug2002, Vol. 27 Issue 4, p58 

    Focuses on the strategy used by pharmaceutical companies in marketing drugs in the U.S. Approval of the Food and Drug Administration on using the antidepressant Paxil in treating generalized anxiety disorder; Idea of Paxil manufacturer GlaxoSmithKline in marketing the disease rather than the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics